Venous Thromboembolism

48
Pipeline Programs
15
Companies
50
Clinical Trials
1 recruiting
7
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
15
3
18
9
Early DiscoveryClinical DevelopmentMarket

On Market (7)

Approved therapies currently available

U
EDOXABANApproved
edoxaban
Unknown Company
oral
Bristol Myers Squibb
ELIQUISApproved
apixaban
Bristol Myers Squibb
oral2025
Bristol Myers Squibb
ELIQUIS SPRINKLEApproved
apixaban
Bristol Myers Squibb
oral2025
Boehringer Ingelheim
PRADAXAApproved
dabigatran etexilate
Boehringer Ingelheim
oral2021
U
RIVAROXABANApproved
rivaroxaban
Unknown Company
oral2025
DS
SAVAYSAApproved
edoxaban tosylate
Daiichi Sankyo
oral2015
J&
XARELTOApproved
rivaroxaban
Johnson & Johnson
Factor Xa Inhibitor [EPC]oral2021

Competitive Landscape

15 companies ranked by most advanced pipeline stage

Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
14 programs
7
4
1
EnoxaparinPhase 31 trial
dabigatran etexilatePhase 31 trial
dabigatran etexilatePhase 31 trial
dabigatran etexilate 150 mg twice dailyPhase 31 trial
BIBR 1048Phase 21 trial
+9 more programs
Active Trials
NCT05536791Withdrawn0Est. Oct 2024
NCT02596230Completed7,797Est. Mar 2019
NCT01153698Terminated167Est. Dec 2011
+11 more trials
Pfizer
PfizerNEW YORK, NY
9 programs
1
1
1
2
ApixabanPhase 41 trial
DalteparinPhase 41 trial
dalteparinPhase 31 trial
dalteparinPhase 21 trial
ApixabanPhase 11 trial
+4 more programs
Active Trials
NCT04969653Completed754,745Est. Jul 2023
NCT05022563Completed55,759Est. Sep 2021
NCT05795062Completed13,945Est. Sep 2023
+5 more trials
DS
Daiichi SankyoChina - Shanghai
8 programs
2
4
1
15mg DU-176bPhase 31 trial
DU-176bPhase 31 trial
edoxabanPhase 31 trial
edoxaban tosylatePhase 31 trial
DU-176bPhase 22 trials
+3 more programs
Active Trials
NCT02952599Completed352Est. Oct 2019
NCT02943993Completed2,809Est. Dec 2020
NCT00806624Completed234Est. Nov 2009
+6 more trials
Bristol Myers Squibb
6 programs
2
1
1
Debriefing and educative componentsPhase 31 trial
ApixabanPhase 11 trial
Apixaban alonePhase 11 trial
ApixabanN/A1 trial
Eliquis (VTE Treatment and Prevention of Recurrent VTE) rPMSN/A1 trial
+1 more programs
Active Trials
NCT01885585Completed100Est. May 2015
NCT02546817Completed29Est. Sep 2017
NCT03087474Completed89,383Est. Jun 2018
+3 more trials
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
2 programs
2
1
XARELTO(Rivaroxaban)Phase 31 trial
XARELTO(Rivaroxaban)Phase 35 trials
Active Trials
NCT00439725Completed1,197Est. Sep 2009
NCT05900388Not Yet Recruiting850Est. Jun 2029
NCT06193863Active Not Recruiting61Est. Dec 2026
+3 more trials
Bayer
BayerLEVERKUSEN, Germany
5 programs
3
RivaroxabanPhase 3
RivaroxabanPhase 3
RivaroxabanPhase 31 trial
Global Anticoagulant Registry in the FIELD- Venous Thromboembolic EventsN/A1 trial
Non-interventional studyN/A5 trials
Active Trials
NCT02155491Completed10,679Est. Sep 2020
NCT03330288Completed1,102Est. Jul 2020
NCT02248610Completed1,343Est. Jul 2020
+4 more trials
E
EisaiChina - Liaoning
2 programs
1
dalteparin injectionPhase 31 trial
Dalteparin sodiumN/A1 trial
Active Trials
NCT01050153Completed50Est. Dec 2011
NCT00876915Terminated218Est. Dec 2014
Hamilton medical
Hamilton medicalSwitzerland - Bonaduz
1 program
1
Anti-Embolism Graduated Pressure StockingsPhase 31 trial
Active Trials
NCT01234064CompletedEst. Dec 2011
HM
Huadong MedicineChina - Hangzhou
1 program
1
RivaroxabanPhase 31 trial
Active Trials
NCT04066764RecruitingEst. Oct 2024
Sanofi
SanofiPARIS, France
2 programs
1
SR123781APhase 2/32 trials
Epidemiology of Venous ThromboembolismN/A1 trial
Active Trials
NCT00456196Completed5,451Est. Jun 2009
NCT00338897Completed1,090Est. May 2007
NCT00123565Completed1,257Est. May 2007
Astellas
AstellasChina - Shenyang
2 programs
2
YM150Phase 2/31 trial
YM150Phase 2/35 trials
Active Trials
NCT00902928Completed1,992Est. Aug 2010
NCT01125657Completed44Est. Mar 2010
NCT01409603Completed26Est. May 2010
+3 more trials
Regeneron
RegeneronTARRYTOWN, NY
3 programs
3
REGN7508Phase 21 trial
REGN9933Phase 21 trial
REGN9933Phase 21 trial
Active Trials
NCT06454630Completed179Est. Jan 2025
NCT06299111Active Not Recruiting195Est. Jun 2026
NCT05618808Completed373Est. May 2024
Ionis Pharmaceuticals
1 program
1
ISIS-FXIRx Dose #2Phase 21 trial
Active Trials
NCT01713361Completed315Est. Aug 2014
Takeda
TakedaTOKYO, Japan
1 program
1
TAK-442Phase 21 trial
Active Trials
NCT00641732Completed1,045Est. Oct 2008
T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
VTE Prophylaxis Guidelines in Hospitalized EldersN/A1 trial
Active Trials
NCT03025100CompletedEst. Mar 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Johnson & JohnsonRivaroxaban
Johnson & JohnsonRivaroxaban
Johnson & JohnsonRivaroxaban
Johnson & JohnsonRivaroxaban
PfizerApixaban
Johnson & JohnsonRivaroxaban
Johnson & JohnsonRivaroxaban
PfizerDalteparin
Johnson & JohnsonRivaroxaban
Huadong MedicineRivaroxaban
Bristol Myers SquibbDebriefing and educative components
Johnson & JohnsonRivaroxaban
BayerRivaroxaban
Johnson & JohnsonRivaroxaban
Johnson & JohnsonRivaroxaban

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 41,865 patients across 50 trials

Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy

Start: Jan 2020Est. completion: Aug 202130 patients
Phase 4Unknown

Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease

Start: Sep 2019Est. completion: May 202290 patients
Phase 4Completed

Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies

Start: Jan 2019Est. completion: Aug 202086 patients
Phase 4Completed

Smartphones to Improve Rivaroxaban ADHEREnce in Atrial Fibrillation

Start: Dec 2016Est. completion: Mar 2018139 patients
Phase 4Completed

Apixaban for the Acute Treatment of Venous Thromboembolism in Children

Start: Nov 2015Est. completion: Apr 2024229 patients
Phase 4Completed

A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department

Start: Oct 2015Est. completion: Mar 2017114 patients
Phase 4Completed

XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis

Start: Jul 2015Est. completion: Jun 201610 patients
Phase 4Terminated

Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients

Start: Jun 2007Est. completion: Jul 200884 patients
Phase 4Terminated

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

Start: Aug 2022Est. completion: May 20281,683 patients
Phase 3Active Not Recruiting

Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters

Start: May 2020Est. completion: Oct 2024
Phase 3Recruiting
NCT04141254Bristol Myers SquibbDebriefing and educative components

Impact of Early Debriefing and Enhanced Educative Components on Direct Oral Anticoagulant Adherence After Venous Thromboembolism.

Start: Dec 2019Est. completion: Dec 2021150 patients
Phase 3Unknown

Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure

Start: Nov 2016Est. completion: Jul 2020112 patients
Phase 3Completed
NCT02583191BayerRivaroxaban

Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients

Start: Mar 2016Est. completion: Aug 2019246 patients
Phase 3Terminated

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Start: Dec 2015Est. completion: Nov 20181,653 patients
Phase 3Terminated

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

Start: Nov 2014Est. completion: Jan 2019500 patients
Phase 3Completed

Safety of Dabigatran Etexilate in Blood Clot Prevention in Children

Start: Sep 2014Est. completion: Nov 2019214 patients
Phase 3Completed

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

Start: Mar 2014Est. completion: Nov 20163,365 patients
Phase 3Completed

Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)

Start: Sep 2013Est. completion: Nov 2019267 patients
Phase 3Completed

Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter

Start: Aug 2013Est. completion: Dec 201460 patients
Phase 3Completed

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Start: May 2013Est. completion: Jul 20162,124 patients
Phase 3Completed

A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy

Start: Feb 2013Est. completion: Oct 2014253 patients
Phase 3Completed

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Start: Oct 2012Est. completion: Jan 20141,504 patients
Phase 3Completed

Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs

Start: Mar 2012Est. completion: Dec 201280 patients
Phase 3Completed

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Start: Mar 2012Est. completion: Jan 201460 patients
Phase 3Completed

Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients

Start: Feb 2012Est. completion: Nov 201340 patients
Phase 3Completed
NCT01234064Hamilton medicalAnti-Embolism Graduated Pressure Stockings

Graduated Compression Stockings (GCS) Pilot Substudy

Start: Nov 2010Est. completion: Dec 2011
Phase 3Completed

Dose-confirmatory Bridging Study in Total Knee Replacement

Start: Oct 2010Est. completion: Jun 2011302 patients
Phase 3Completed

Dose-confirmatory Bridging Study in Total Hip Replacement

Start: Sep 2010Est. completion: Aug 2011402 patients
Phase 3Completed

Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement

Start: Mar 2010Est. completion: Dec 201056 patients
Phase 3Completed
NCT00986154Daiichi Sankyoedoxaban tosylate

Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).

Start: Oct 2009Est. completion: Apr 20138,292 patients
Phase 3Completed
NCT00876915Eisaidalteparin injection

A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients

Start: Jul 2009Est. completion: Dec 2014218 patients
Phase 3Terminated

Prevention of Venous Thromboembolism in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower Extremities

Start: Jun 2009Est. completion: Apr 2010101 patients
Phase 3Completed

Prevention of Recurrence of Venous Thromboembolism in Patients With a History of Venous Thromboembolism

Start: Jun 2009Est. completion: Dec 201087 patients
Phase 3Completed

A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

Start: Jun 2009Est. completion: Apr 2010156 patients
Phase 3Completed

YM150 for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness

Start: May 2009Est. completion: Apr 201052 patients
Phase 3Completed

A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty

Start: Mar 2009Est. completion: Feb 2010716 patients
Phase 3Completed

Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery

Start: Oct 2008Est. completion: Feb 201092 patients
Phase 3Completed

Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty

Start: Mar 20082,055 patients
Phase 3Completed

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients

Start: Dec 2007Est. completion: Nov 20108,101 patients
Phase 3Completed
NCT00558259Boehringer Ingelheimdabigatran etexilate 150 mg twice daily

Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE

Start: Nov 20071,353 patients
Phase 3Completed

Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

Start: Feb 2007Est. completion: Sep 20091,197 patients
Phase 3Completed

Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients

Start: Oct 2002Est. completion: Nov 2006512 patients
Phase 3Completed

Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery

Start: May 2009Est. completion: Mar 2010610 patients
Phase 2/3Completed

Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery

Start: May 2009Est. completion: Jan 2010369 patients
Phase 2/3Completed

A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery

Start: Apr 2009Est. completion: Aug 20101,992 patients
Phase 2/3Completed

Dose Ranging Study in Elective Total Hip Replacement Surgery

Start: May 2006Est. completion: May 20071,090 patients
Phase 2/3Completed

A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)

Start: Sep 2024Est. completion: Jun 2026195 patients
Phase 2Active Not Recruiting

A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants

Start: Jun 2024Est. completion: Jan 2025179 patients
Phase 2Completed

A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants

Start: May 2023Est. completion: May 2024373 patients
Phase 2Completed

Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery

Start: Jul 2018Est. completion: Dec 2023272 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

18 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 41,865 patients
15 companies competing in this space